1. Home
  2. DIBS vs PYXS Comparison

DIBS vs PYXS Comparison

Compare DIBS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 1stdibs.com Inc.

DIBS

1stdibs.com Inc.

HOLD

Current Price

$4.23

Market Cap

164.7M

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.03

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DIBS
PYXS
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.7M
141.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DIBS
PYXS
Price
$4.23
$3.03
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$7.00
AVG Volume (30 Days)
71.7K
1.0M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
22.45
3.03
EPS
N/A
N/A
Revenue
$89,620,000.00
$13,858,000.00
Revenue This Year
$3.12
N/A
Revenue Next Year
$1.72
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
1.54
N/A
52 Week Low
$2.50
$0.97
52 Week High
$6.62
$5.55

Technical Indicators

Market Signals
Indicator
DIBS
PYXS
Relative Strength Index (RSI) 44.88 59.41
Support Level $3.97 $1.22
Resistance Level $4.83 $3.40
Average True Range (ATR) 0.21 0.25
MACD -0.03 0.02
Stochastic Oscillator 35.29 82.38

Price Performance

Historical Comparison
DIBS
PYXS

About DIBS 1stdibs.com Inc.

1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: